186 related articles for article (PubMed ID: 17425643)
1. Cutaneous cryptococcosis with alemtuzumab in a patient treated for chronic lymphocytic leukaemia.
Dilhuydy MS; Jouary T; Demeaux H; Ravaud A
Br J Haematol; 2007 Jun; 137(6):490. PubMed ID: 17425643
[No Abstract] [Full Text] [Related]
2. Efficacy of alemtuzumab in cutaneous chronic lymphocytic leukaemia involving facial skin.
Grey M
Br J Haematol; 2008 Jul; 142(1):1. PubMed ID: 18477054
[No Abstract] [Full Text] [Related]
3. Atypical presentation of varicella zoster in a patient on alemtuzumab.
Venkatachalapathy S; Crowe J; Gray A
Br J Haematol; 2007 Aug; 138(4):406. PubMed ID: 17659051
[No Abstract] [Full Text] [Related]
4. Chronic lymphocytic leukemia with eyelid involvement responding to alemtuzumab.
Laurenti L; Tarnani M; Innocenti I; Savino G; Battendieri R; Larocca LM; Chiusolo P; Sorà F; Sica S; Efremov D; Leone G
J Clin Oncol; 2008 Nov; 26(32):5299-301. PubMed ID: 18854557
[No Abstract] [Full Text] [Related]
5. Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature.
Bassetti M; Repetto E; Mikulska M; Miglino M; Clavio M; Gobbi M; Righi E; Viscoli C
J Chemother; 2009 Apr; 21(2):211-4. PubMed ID: 19423476
[TBL] [Abstract][Full Text] [Related]
6. Campath-1H for chronic lymphocytic leukemia.
Rai KR
Clin Lymphoma; 2002 Sep; 3(2):73-4. PubMed ID: 12435278
[No Abstract] [Full Text] [Related]
7. Disseminated cryptococcosis, invasive aspergillosis, and mucormycosis in a patient treated with alemtuzumab for chronic lymphocytic leukaemia.
Henn A; Mellon G; Benoît H; Roos-Weil D; Jauréguiberry S; Mordant P; Fekkar A; Caumes E
Scand J Infect Dis; 2014 Mar; 46(3):231-4. PubMed ID: 24450842
[TBL] [Abstract][Full Text] [Related]
8. Low-dose intravenous alemtuzumab therapy in pretreated patients affected by chronic lymphocytic leukemia. A single center experience.
Laurenti L; Piccioni P; Tarnani M; Efremov DG; Fiorini A; Garzia M; Sica S
Haematologica; 2005 Aug; 90(8):1143-5. PubMed ID: 16079121
[TBL] [Abstract][Full Text] [Related]
9. Alemtuzumab in chronic lymphocytic leukemia.
James DF; Kipps TJ
Future Oncol; 2007 Feb; 3(1):29-42. PubMed ID: 17280499
[TBL] [Abstract][Full Text] [Related]
10. Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation.
Karlsson C; Norin S; Kimby E; Sander B; Porwit Macdonald A; Nilsson B; Johansson E; Mellstedt H; Lundin J; Osterborg A
Leukemia; 2006 Dec; 20(12):2204-7. PubMed ID: 17051245
[No Abstract] [Full Text] [Related]
11. Advances in the use of alemtuzumab in CLL.
Stilgenbauer S
Clin Adv Hematol Oncol; 2008 Jan; 6(1):23-4. PubMed ID: 18322437
[No Abstract] [Full Text] [Related]
12. Campath-1H induced pure red cell aplasia in a patient with chronic lymphatic leukaemia.
Thachil J; Salim R
Leuk Res; 2007 Jul; 31(7):1025-6. PubMed ID: 17005249
[No Abstract] [Full Text] [Related]
13. NCCN: New directions in chronic lymphocytic leukemia.
O'Brien S
Cancer Control; 2001; 8(6 Suppl 2):114-7. PubMed ID: 11760553
[No Abstract] [Full Text] [Related]
14. What choices are available for treatment of the patient with chronic lymphocytic leukemia who is fludarabine-refractory?
Byrd JC; Rai KR
Semin Oncol; 2000 Aug; 27(4):xii-xv; discussion xv-xvi. PubMed ID: 10950363
[No Abstract] [Full Text] [Related]
15. Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.
Ferrajoli A; Wierda WG; LaPushin R; O'Brien SM; Faderl S; Browning ML; Keating MJ
Eur J Haematol; 2008 Apr; 80(4):296-8. PubMed ID: 18182081
[TBL] [Abstract][Full Text] [Related]
16. Disseminated molluscum contagiosum in a patient with chronic lymphocytic leukaemia after alemtuzumab.
Pitini V; Arrigo C; Barresi G
Br J Haematol; 2003 Nov; 123(4):565. PubMed ID: 14616955
[No Abstract] [Full Text] [Related]
17. Severe liver dysfunction from hepatitis C virus reactivation following alemtuzumab treatment for chronic lymphocytic leukaemia.
Anoop P; Wotherspoon A; Matutes E
Br J Haematol; 2010 Feb; 148(3):484-6. PubMed ID: 19874308
[No Abstract] [Full Text] [Related]
18. Mycobacterium haemophilum infection after alemtuzumab treatment.
Kamboj M; Louie E; Kiehn T; Papanicolaou G; Glickman M; Sepkowitz K
Emerg Infect Dis; 2008 Nov; 14(11):1821-3. PubMed ID: 18976587
[No Abstract] [Full Text] [Related]
19. Tuberculosis due to Mycobacterium bovis after alemtuzumab administration.
Abad S; Gyan E; Moachon L; Bouscary D; Sicard D; Dreyfus F; Blanche P
Clin Infect Dis; 2003 Jul; 37(2):e27-8. PubMed ID: 12856232
[TBL] [Abstract][Full Text] [Related]
20. Alemtuzumab: effective monotherapy for simultaneous B-cell chronic lymphocytic leukaemia and Sézary syndrome.
Gibbs SD; Herbert KE; McCormack C; Seymour JF; Prince HM
Eur J Haematol; 2004 Dec; 73(6):447-9. PubMed ID: 15522069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
